Peter Szijj
Seminars
As the field expands beyond traditional cytotoxic payloads toward degraders and other complex, hydrophobic modalities, linker and conjugation chemistry must evolve to solve escalating biophysical challenges. From high-DAR constructs to degrader-antibody conjugates, the central question emerges: how do we push payload complexity and loading capacity without compromising stability, manufacturability, or in vivo performance?
Join leading experts as they discuss how novel linker architectures, advanced analytical precision, and site-selective
conjugation strategies can be integrated into cohesive platforms by:
- Balancing high payload loading with biophysical stability, examining how innovative linker architectures and hydrophobicity mitigating designs can enable DAR 8 and greater while preserving solubility, structural integrity, and favorable pharmacokinetics
- Redefining conjugation control as a platform enabler, debating how pyridazinedione-based site-selective strategies and advanced analytical tools can deliver precise, homogeneous DAR control to unlock reproducible, scalable next-generation constructs
- Harnessing traceless and site-specific linker strategies to enable emerging modalities, evaluating how degrader-compatible, hydrophobicity-masking, and cleavable designs can expand the ADC paradigm to include degrader-antibody conjugates and other novel payload classes without sacrificing developability or therapeutic index
Focusing on the high-value challenge of improving established cytotoxins, this hands-on workshop tackles the "why now" of evolving chemistry for traditional payloads. Providing a tactical playbook for leveraging next-generation linker design and site-specific conjugation to overcome the limitations of first-generation ADCs and achieve best-inclass profiles.
This is a must-attend for teams looking to maximum the value of proven payloads by understanding that where you attach is as important as what you attach by:
This workshop will gather experts to discuss:
- Systematically evaluating how strategic changes to the conjugation site impact critical attributes such as antibody stability, antigen binding, and off-target toxicity profiles
- Benchmarking novel linker designs, from peptide-based to hydrophilic polymer shields to assess their ability to improve solubility, reduce aggregation, and enable higher DARs without compromising tolerability in traditional payloads.
- Building a comparative case study on site-specific vs. stochastic conjugation for a traditional payload, analyzing hard data on homogeneity, pharmacokinetic consistency, and manufacturability to justify the investment in advanced conjugation technologies
